Schizophrenia is classified as a chronic brain disorder by the American Psychiatric Association, and decades of imaging, genetic, and molecular research support that classification. People with schizophrenia show measurable differences in brain structure, brain chemistry, and the way brain regions communicate with each other. That said, the picture is more nuanced than a simple “yes.” No blood test or brain scan can diagnose it, the biological changes interact heavily with environmental factors, and not everyone with schizophrenia shows the same pattern of brain abnormalities.
What Brain Scans Actually Show
The most consistent structural finding in schizophrenia is a reduction in gray matter, the tissue that contains the brain’s nerve cell bodies and does most of the heavy cognitive lifting. A meta-analysis of imaging studies found an overall reduction of about 4% in gray matter volume in people with schizophrenia compared to healthy controls. Alongside that, the fluid-filled cavities inside the brain (the lateral and third ventricles) are visibly enlarged, which reflects the surrounding tissue loss.
These aren’t just static snapshots. A large longitudinal study that followed people from their first psychotic episode found that brain tissue loss is progressive, not a one-time event. The losses were greatest during the early stages of the illness, particularly in the frontal lobes and the thalamus, a deep brain structure that acts as a relay hub for sensory and cognitive signals. After that initial period of rapid change, the rate of tissue loss slowed and began to resemble what happens in healthy aging. Importantly, this progressive change occurred only in a subset of patients, not universally.
Beyond volume, the wiring between brain regions is also affected. Diffusion imaging, which tracks the structural integrity of the brain’s white matter pathways, reveals widespread abnormalities across both hemispheres in people with schizophrenia. The fiber tracts that connect the frontal lobes to other regions are less organized, even when the total volume of white matter appears normal. This has led researchers to describe schizophrenia as a “disconnection syndrome,” where the problem isn’t just damaged regions but degraded communication between them.
How Brain Networks Misfire
Functional brain imaging tells a complementary story. When healthy people are resting and not focused on a task, a set of brain regions called the default mode network hums along in a coordinated pattern. In schizophrenia, this network tends to be hyperconnected internally, meaning its components are locked into unusually tight synchrony. At the same time, the normal push-pull relationship between this resting network and the networks that activate during focused tasks is disrupted. The brain has trouble toggling between inward-directed thought and outward-directed attention, which may help explain symptoms like disorganized thinking, difficulty concentrating, and the intrusion of internal experiences (like hallucinations) into waking awareness.
The Chemistry Behind Symptoms
Two chemical messenger systems in the brain are central to schizophrenia. The first and longest-studied is dopamine. Brain imaging consistently shows that people with schizophrenia have elevated dopamine production and release capacity in the striatum, a region involved in motivation, reward, and the assignment of importance to stimuli. Too much dopamine signaling here is thought to make the brain tag irrelevant stimuli as meaningful, contributing to delusions and hallucinations.
The second system involves glutamate, the brain’s primary excitatory messenger. Drugs that block a specific glutamate receptor produce symptoms that closely mimic schizophrenia, including not just psychosis but also the cognitive and motivational deficits that dopamine-focused explanations struggle to account for. Genetic studies have reinforced this link: many of the gene variants associated with schizophrenia risk are involved in glutamate signaling and synapse development, while surprisingly few directly affect the dopamine system. The current scientific picture is that glutamate dysfunction may be closer to the root cause, with dopamine abnormalities emerging downstream as a consequence.
A Genetic Foundation With Environmental Triggers
Schizophrenia has one of the strongest genetic components of any psychiatric condition. The lifetime risk in the general population sits just below 1%, but for an identical twin of someone with schizophrenia, that risk jumps to roughly 40 to 50%. For non-identical twins, it falls to about 10 to 19%. That gap between identical twins (who share all their DNA) and the general population makes clear that genes play a major role. But the fact that identical twins are concordant only about half the time, not 100%, makes equally clear that genes alone don’t determine who develops the disorder.
Environmental factors fill that gap. One well-studied example is cannabis use. In people who already carry a high genetic risk for schizophrenia, heavy cannabis use is associated with reduced white matter volume in the frontal and temporal lobes and thinner cortex, both of which are known features of the disorder. Cannabis doesn’t cause schizophrenia on its own, but in genetically vulnerable individuals, it appears to accelerate or worsen the brain changes that underlie it. Other environmental risk factors that interact with genetic predisposition include prenatal infections, childhood adversity, and urban upbringing, though the biological mechanisms for these are less precisely mapped.
Why It Typically Emerges in Late Adolescence
One of the most telling clues that schizophrenia is rooted in brain biology is its timing. Symptoms most commonly appear in the late teens to mid-twenties, which coincides with a major phase of brain remodeling. During adolescence, the brain undergoes synaptic pruning, a normal process in which excess connections between neurons are stripped away to make circuits more efficient. This is especially active in the prefrontal cortex, the region responsible for planning, decision-making, and social behavior.
A landmark genetic discovery linked this process directly to schizophrenia risk. A gene called C4, part of the immune system’s complement pathway, was found to be overexpressed in people who develop the disorder. In animal studies, overexpression of C4 in prefrontal cortex neurons led to roughly 30% fewer dendritic spines (the tiny structures where neurons receive signals) and about a 60% decrease in the frequency of excitatory connections. The mechanism involves microglia, the brain’s immune cells, which use complement proteins like C4 as “eat me” tags to identify synapses for removal. When C4 is overproduced, microglia prune too aggressively, stripping away connections that should have been kept. The result is a prefrontal cortex that is underconnected, mirroring the gray matter loss and reduced connectivity seen in people with schizophrenia.
Why It’s Not Diagnosed Like Other Brain Diseases
Despite all this biological evidence, schizophrenia is still diagnosed entirely through clinical observation: a psychiatrist evaluates symptoms, their duration, and their impact on functioning. There is no FDA-approved blood test, brain scan, or biomarker for schizophrenia. As of 2025, the only psychiatric-adjacent conditions with validated diagnostic biomarkers are Alzheimer’s disease (a blood test measuring specific protein ratios) and opioid use disorder (a genetic risk test). For schizophrenia, no single biomarker has achieved the sensitivity and specificity needed for routine clinical use.
This doesn’t mean the brain changes aren’t real. It means they overlap too much with other conditions and with normal variation to serve as a reliable diagnostic tool for any individual patient. A 4% average reduction in gray matter, for instance, is a robust finding across large groups but falls well within the range of normal brain size differences between any two people. The same is true for dopamine levels and white matter integrity. These are population-level patterns, not individual fingerprints.
So schizophrenia occupies an unusual position: it is a brain disease by every measure researchers can apply to groups of patients, but it cannot yet be confirmed through the kind of objective test that defines conditions like diabetes or Alzheimer’s. The biology is real and measurable. The diagnostic tools just haven’t caught up.